Uveitis Treatment Market Size Worth USD 1078.99 Million By 2032

Market Summary: The global uveitis treatment market had a value of USD 638.65 million in 2022 and is projected to reach USD 1078.99 million by 2032, with a forecasted revenue compound annual growth rate (CAGR) of 6% over the mentioned period. Uveitis, characterized by inflammation in the uvea of the eye, comprising the iris, ciliary body, and choroid, can lead to serious consequences like glaucoma, cataracts, and permanent vision loss if left untreated. It’s noteworthy that uveitis ranks as the fifth leading cause of blindness in the United States, affecting nearly 150,000 individuals, as per the National Eye Institute.

Get a sample copy of the Uveitis Treatment Market report: https://www.reportsanddata.com/download-free-sample/5183

Key Players: Prominent companies in the global uveitis treatment market include Alimera Sciences, Inc., Bausch Health Companies Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., AbbVie Inc., Allergan plc, Novartis AG, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., and Genentech, Inc.

Strategic Developments:

  • EyePoint Pharmaceuticals, Inc. conducted Phase 3 trials of Yutiq, a micro-insert for non-infectious uveitis affecting the posterior eye, which showed positive results in 2021. Yutiq was found to reduce the need for frequent injections and provide sustained inflammation control in uveitis patients.
  • Regeneron Pharmaceuticals, Inc. reported positive results from Phase 2 trials of intravitreal aflibercept for the treatment of non-infectious uveitis affecting the posterior eye in 2021. Aflibercept significantly improved macular thickness and visual acuity in uveitis patients.
  • Aura Biosciences developed therapeutic candidate AU-011 for the treatment of uveal melanoma and other ocular cancers, as announced by Clearside Biomedical, Inc. in 2020. The agreement includes a down payment, development milestones, and royalties on net sales.

Factors Driving Market Growth: The growth in the uveitis treatment market can be attributed to the increased utilization of Biologics and Biosimilars for the treatment of various diseases, including autoimmune conditions like uveitis. These biologics, derived from live cells, are effective and safe, and biosimilars, which are more cost-effective, have also gained popularity. The demand for biologics and biosimilars is on the rise due to their ability to provide targeted treatment with fewer side effects.

Additionally, the introduction of novel treatment options is contributing to the market’s growth. New medications such as Adalimumab, approved by the FDA for the treatment of non-infectious intermediate, posterior, and panuveitis, are making a significant impact. Furthermore, ongoing research and development are expected to lead to more treatment options, such as Suprachoroidal CLS-TA, a medication delivery device by Clearside Biomedical designed for macular edema in non-infectious uveitis.

The emphasis on early diagnosis and treatment of uveitis is another driver for market growth, as early detection and management can prevent disease progression and reduce complications. The development of advanced imaging and diagnostic tools is aiding this effort.

Challenges: However, the high cost of care and limited medication availability in some regions could impede the uveitis treatment market’s growth.

Market Segmentation: The uveitis treatment market is segmented into four categories based on the type of uveitis: Anterior, Posterior, Intermediate, and Panuveitis. Each category has specific characteristics and treatment needs, resulting in varying revenue shares.

  • Anterior Uveitis: This segment held the largest revenue share in 2022, primarily due to the high prevalence of uveitis affecting the iris and ciliary body at the front of the eye. The market for anterior uveitis is expected to maintain a substantial share, especially in emerging economies, due to its increasing prevalence and the availability of various treatment options, including biologics, immunosuppressive drugs, and corticosteroids.
  • Posterior Uveitis: The market for posterior uveitis is expected to experience a high revenue CAGR over the forecast period because of its increasing prevalence, affecting the back of the eye, including the retina and choroid. Novel therapeutic options, including biologics, corticosteroids, and immunosuppressive drugs, are driving revenue growth, and advancements in drug delivery systems are expected to further fuel this market.
  • Intermediate Uveitis: The intermediate uveitis market is anticipated to expand significantly due to the rising prevalence of uveitis affecting the middle of the eye, including the retina and vitreous humor. Several therapeutic options, such as biologics, immunosuppressive drugs, and corticosteroids, are expected to drive revenue growth in this segment.
  • Panuveitis: Panuveitis, affecting all regions of the eye, is projected to see a high CAGR during the forecast period. Novel treatment options, including biologics, corticosteroids, and immunosuppressive drugs, are expected to contribute to revenue growth, along with increased awareness of early identification and treatment of uveitis.

Treatment Types: The uveitis treatment market is categorized based on the type of treatment, including Corticosteroids, Immunosuppressants, Biologics, and Others.

  • Corticosteroids: Corticosteroids play a significant role in this market, as they are often the first-line treatment due to their potent anti-inflammatory properties. They are effective in relieving uveitis symptoms and are cost-effective.
  • Immunosuppressants: This segment is expected to experience the fastest revenue CAGR, particularly when corticosteroids are ineffective or cause side effects. Immunosuppressants weaken the immune system and are used to treat uveitis, particularly in cases of posterior uveitis and panuveitis.
  • Biologics: Biologics, designed to target specific immune system components responsible for uveitis-related inflammation, are gaining importance, especially when other treatments fail. The availability of new pharmaceuticals in development and increased accessibility of biologics are driving revenue growth.
  • Others: This category includes drugs like antibiotics, antivirals, and antifungals used to treat infectious uveitis or prevent infections caused by other uveitis medications. The segment’s growth is expected to be slower due to limited use and lower costs.

Regional Outlook: North America leads the global uveitis treatment market due to the high prevalence of uveitis cases in the region, particularly in the United States. The expansion of the market is driven by the rising incidence of autoimmune diseases and advanced healthcare infrastructure.

The Asia Pacific region is expected to witness significant growth in the uveitis treatment market. The rising prevalence of uveitis patients in countries like India and China, coupled with an aging population, is driving the demand for effective therapies. The availability of advanced treatment options and growing uveitis awareness are contributing to the market’s growth.

Europe, with a significant population affected by autoimmune diseases, is a crucial market for uveitis treatment. The need for efficient treatment options in the region is fueled by the increasing incidence of conditions like HIV, sarcoidosis, and multiple sclerosis. Investments in research and development and public awareness initiatives are further propelling the market in Europe.

Explore Trending Reports:

Ice Chests and Coolers Market-https://www.globenewswire.com/news-release/2019/11/07/1943396/0/en/Ice-Chests-and-Coolers-Market-To-Reach-USD-1-051-5-Million-by-2026-Reports-And-Data.html

Pulse Flour Market-https://www.globenewswire.com/news-release/2019/09/23/1919367/0/en/Global-Pulse-Flour-Market-To-Reach-USD-28-9-Billion-By-2026-Reports-And-Data.html

Beta-Carotene Market-https://www.globenewswire.com/news-release/2020/03/12/1999815/0/en/Beta-Carotene-Market-To-Reach-USD-654-0-Million-By-2027-Growing-at-a-CAGR-of-3-3-Reports-and-Data.html

Dietary Fibers Market-https://www.globenewswire.com/news-release/2019/10/14/1929296/0/en/Dietary-Fibers-Market-To-Reach-USD-10-77-Billion-By-2026-Reports-And-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5183

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release